Report on the antiemetic effectivity of a single 1 mg oral granisetron in moderately emetogenic chemotherapies of gynecological malignancies
Lehoczky, O.
European Journal of Gynaecological Oncology 19(5): 449-452
1998
ISSN/ISBN: 0392-2936 PMID: 9863909 Document Number: 1889
Objective: On the basis of the relatively long 9-12 hour plasma-half-life of the highly selective serotonin antagonist granisetron (GRAN) and on observations that emetic episodes are detected mainly 10 hours after starting chemotherapy it was supposed that a single 1 mg oral GRAN (KytrilTM, SmithKline Beecham) is enough to prevent the emesis of moderately emetogenic chemotherapies. Materials and methods: A total of 45 gynecological cancer patients were treated in 115 chemotherapy cycles with a single I mg oral GRAN in a prospective, non-randomized study. Patients stayed in hospital for 24 hours after chemotherapy and emetic episodes were registered on special charts. Results: A complete response (CR) of 83.4% was found in the 115 cycles. Thirty-seven of the total 45 patients with ovarian cancer had a 84.7% CR in the first 24 hours of chemotherapy. In 29 patients 50 mg/ml cisplatin was administered with a 79.9% CR. Conclusions: 1 mg oran GRAN is a suitable antiemetic therapy in moderately emetogenic chemotherapies.
Document emailed within 1 workday
